ADORA2A and renal cell carcinoma: Of those, a cohort of 68 renal cell carcinoma (RCC) patients yielded clinical responses, including partial responses (PR) in 11% of patients treated with a combination of A2AR antagonists and anti-PD-L1 antibodies, and in 3% of patients treated with A2AR antagonists alone[146].